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Abstract
X-linked adrenoleukodystrophy (X-ALD) affects the nervous system white matter and adrenal cortex secondary to mutations
in the ABCD1 gene that encode the peroxisomal membrane protein. We conducted a genomic and protein expression study
of susceptibility gene with its clinical and biochemical analysis. To the best of our knowledge this is the first preliminary
comprehensive study in Indian population that identified novel mutations and SNPs in a relatively large group. We screened
17 Indian indigenous X-linked adrenoleukodystrophy cases and 70 controls for mutations and SNPs in the exonic regions
(including flanking regions) of ABCD1 gene by direct sequencing with ABI automated sequencer along with Western blot
analysis of its endogenous protein, ALDP, levels in peripheral blood mononuclear cells. Single germ line mutation was
identified in each index case in ABCD1 gene. We detected 4 novel mutations (2 missense and 2 deletion/insertion) and 3
novel single nucleotide polymorphisms. We observed a variable protein expression in different patients. These findings
were further extended to biochemical and clinical observations as it occurs with great clinical expression variability. This is
the first major study in this population that presents a different molecular genetic spectrum as compared to Caucasian
population due to geographical distributions of ethnicity of patients. It enhances our knowledge of the causative mutations
of X-ALD that grants holistic base to develop effective medicine against X-ALD.
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Introduction
X-linked adrenoleukodystrophy (X-ALD; OMIM # 300100) is
one of the most frequent monogenic inherited peroxisomal
neurodegenerative disorders. It affects the cerebral white matter,
peripheral nerves, adrenal cortex and testis [1]. It is a recessive,
usually male lethal, serious and progressive genetic disorder
characterized by abnormal accumulation of saturated very long
chain fatty acids (VLCFA) in body fluids and affected tissues, most
notably in the brain and adrenal cortex due to an impaired b-
oxidation in peroxisomes [1–4]. The frequency of X-ALD in USA
is 1:21,000 in males [5]. Seven different phenotypes have been
described for male and five for female patients [6]. The more
frequent male clinical phenotypes are cerebral form and
adrenomyeloneuropathy (AMN). The cerebral forms viz. child-
hood, adolescent, and adult are characterized by intellectual,
behavioral, cognitive, visual, gait disturbances associated with a
rapid neurological progression, inflammatory reaction in the
cerebral white matter and increased expression of cytokines which
may involve autoimmune mechanisms [7,8]. AMN, present only
in adults, is characterized by gait, sensory, autonomic disturbances
with slower progression, inflammatory response absent or mild
and may affect the spinal cord and peripheral nerves. About 35%
of AMN patients develop cerebral involvement at a later stage
[6,7]. Other less frequent phenotypes include asymptomatic, olivo-
ponto-cerebellar (OPC) and Addison-only disorders (6). These
different phenotypes might appear within the same family due to
an identical ABCD1 gene mutation [9–12,24]. Additional genetic
or environmental/epigenetic/stochastic factors have been suggest-
ed as the modulator of clinical phenotypes due to lack of any
established genotype-phenotype correlation [13–15]. Moreover,
the accurate molecular events from metabolic phase, characterized
by cytoplasmic accumulation of VLCFA, to neuroinflammation
and demyelination or axonal degeneration are still obscure.
However, there are a few therapeutic approaches are under
evaluation to control the devastating course of this disease. For
many years dietary treatment based on a mixture of glyceroyl
trioleate and glyceroyl trierucate (Lorenzo’s oil) has been practiced
as a preventive therapy [16]. Hydrocortisone replacement threapy
was found to be useful in adrenal insufficiency X-ALD patients
[17]. The progression of this disease was successfully halted by
allogeneic hematopoietic cell transplantation (HCT) [18]. Recent-
ly, lentiviral-mediated gene therapy of hematopoietic stem cells
was reported to provide clinical benefits in X-ALD patients [19].
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gene defective in X-ALD was mapped to Xq28 [20]. It is 21 kb
long gene, composed of 10 exons and codes for mRNA of 4.3 kb
that is finally translated into 745 amino acid long peroxisomal
ABC transporter adrenoleukodystrophy protein (ALDP), [21]. The
imperfect ALDP leads to accumulation of saturated very long
chain fatty acids (VLCFAs) in cytoplasm, which have to be
exclusively catabolized by peroxisomal b-oxidation [22]. The
biochemical diagnosis of X-ALD patients and carriers is based on
the elevated level of VLCFA in plasma [23]. However, in 0.1% of
affected males, the plasma C26:0 level is at borderline of the
healthy subjects and 15% female heterozygotes have normal levels
of VLCFA [24]. Molecular analysis with mutation detection is the
only effective and reliable method to unambiguous determination
of the genetic status of each individual at risk and to accurately
rule out carrier status in females [25]. In the present study, we
examined the mutations and SNPs in ABCD1 gene in 17 patients
with adrenoleukodystrophy, including 2 carrier females and 70
controls and report here the full spectrum of molecular defects of
these patients describing the clinical features related to ABCD1
gene mutations.
Materials and Methods
Patient Selection
The study included 17 patients of Indian origin (northern,
southern and north-west region) attending the Department of
Pediatrics and Department of Neurology, AIIMS, New Delhi or
Department of Pediatrics, Lady Hardinge Medical College,
University of Delhi, Delhi. The study population included fifteen
male and two female carriers. Seventy healthy subjects (56 males
and 14 females) were enrolled as normal controls. The study was
initiated after obtaining the approval of the Institutional Ethics
Committees, All India Institute of Medical Sciences (AIIMS), Lady
Hardinge Medical College and Vallabhbhai Patel Chest Institute,
Delhi and written informed consent was taken from all individuals
(parents in case of children) participating in the study. The
diagnosis of the X-ALD patients was based on clinical assessment,
MRI and VLCFA analysis. Further categorization of the patients
in different phenotypes of X-ALD was done according to the age
of onset of the disease and the organ principally affected. The
neurological examination was geared towards detection of
behavioral disturbances, impaired cognition, and dementia in
symptomatic patients, and included evaluation of higher mental
function, cranial nerve, motor and cerebellar system function.
Neurophysiologic examination included motor nerve conduction,
F-wave and sensory nerve conduction studies. Phenotype specific
T2 signal hyperintensity MRI characteristic patterns were
observed in different X-ALD patients. All patients included in
our study had elevated plasma levels of VLCFA particularly
C26:0/C22:0 and C24:0/C22:0 ratios.
Molecular Genetic Analysis
Peripheral blood (10 ml) was drawn from all patients (ccALD
and AdolCALD) and their mothers, in sterile EDTA vacutainers
(Greiner bio-one international, Germany). Genomic DNA was
isolated from the blood leukocytes, using phenol-chloroform
protocol [26]. All the 10 exons of ABCD1 gene, including the
flanking region of each exon (exon-intron boundaries), were
amplified by polymerase chain reaction. The primers for
amplification of first six exons (Table 1) of ABCD1 gene were
designed with DNASTAR (DNASTAR Inc., Madison, WI)
software, and their specificity was confirmed by the Basic Local
Alignment Search Tool in the Human Genome Database at the
National Centre for Biotechnology Information (Bethesda, MD).
M13-tailed primers were used for exons seven to ten due to the
existence of paralogs copies on chromosome 2p11, 10p11, 16p11
and 22q11 [25,27]. All exons were amplified in 50 ml volumes
containing 10 mM Tris (pH 9), 50 mM KCl, 1.5 mM MgCl2,
0.01% gelatin, 0.2 mM each dNTP, 0.4 mM each forward and
reverse primers, 1.5 unit of Taq DNA polymerase (Bangalore
Genei Pvt. Ltd., India), and 80 ng of genomic DNA template.
PCR was performed for first six exons of ABCD1 gene of by 35
cycles with the MJ Research Peltier Thermal Cycler (GMI Inc.,
Ramsey, MN)/Touchgene Gradient 200 (Techne Ltd., Cam-
bridge, United Kingdom). Each cycle consisted of 30 s at 94uC for
denaturation, 30 s at 56–62uC for annealing (depending upon the
primers sets used), 30 s at 72uC for extension, and 10 min for final
extension at 72uC. The amplification of exons 7 to 10 were
performed in addition to 0.5 M betaine with PCR conditions as
94uC for 5 min, 35 cycles of 94uC for 45 s and 70uC for 1 min.
Polymerase chain reaction amplicons were purified by removing
excess primers and nucleotides, by using DNA isolation kit
(Biological Industries, Kibbutz Beit Haemek, Israel). Direct
sequencing of the ABCD1 gene of X-ALD patients and control
samples were performed using ABI 3100 DNA automated
sequencer with BigDye cycle sequencing ready reaction (Applied
Biosystems Inc., Foster City, CA) (Figure 1, Supporting Informa-
tion S1 and S2).
PBMC cell lysis
Peripheral blood mononuclear cells (PBMC) were isolated from
whole blood using ficoll density gradient centrifugation at 6706g
for 30 minutes. Cells were washed with 1xPBS and cell pellet lysed
in ice-cold 100–200 ml of radioimmunoprecipitation assay (RIPA)
Table 1. Primers and cyclic conditions used for the amplification of the coding and intron-exons boundaries of ABCD1.
(Exon/s)
* Forward Primer (59-39) Reverse Primer (59-39) Annealing Temp. (6C) Fragment Length (bp)
1a GGAGGAGGAGAAGGTGGAGAGG AGACGGCTGCGGAACGACA 64 834
1b CCTCATCGCCCTCCCTGCTACCTT GCCTCCCTGCCACACGCTTCC 64 538
2 GGCCCCACCCAATCGTAAC CAGCGGTATGGGGGACAGG 56 392
3 & 4 GCCTGTGATGTGCTCTGGGTTGGT TGAGTGAGGGAGCGGGAATAG 62 704
5 CCAGGGGCACGCAGACTC GGAACGCCGGGGTGAAC 60 408
6 CAGGAGGCCATAGGGTACGGGAA GCAGTGGATCGGGCGGGTTTG 56 372
*Exon one was amplified into two amplicons 1a and 1b due to its large size while exon 3 and 4 are amplified into a single amplicon due to their relatively small size.
Exon 7–10 were amplified by M13 tailed primers
25.
doi:10.1371/journal.pone.0025094.t001
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280uC.
Western blot analysis
Total protein contents were determined with Pierce BSA total
protein assay kit (Thermo Fisher Scientific Inc., Pierce Protein
Research Products, Rockford, IL USA). Equal amount of protein
extract (150 mg of total protein per lane) were loaded on 12% tris-
glycine gradient SDS-polyacrylamide gel with Amersham full
range Rainbow protein molecular weight marker (GE Healthcare
UK Limited Amersham Place, Buckinghamshire, UK), electro-
phoresed and transferred to nitrocellulose membrane (Advanced
Microdevices Pvt. Ltd, Ambala Cantt, India). Membranes were
blocked with 5% blotto, non fat dry milk powder (Santa Cruz
Biotechnology Inc., Santa Cruz, CA. USA) in TBST (20 mM Tris;
pH 7.5, 500 mM NaCl, 0.05% Twee 20). Membrane was
incubated with primary antibody mouse anti-ALDP monoclonal
antibody, MAB2162 (1:500; Chemicon International, Millipore,
Billerica, MA USA). A rabbit anti-mouse horseradish peroxidase
conjugated secondary antibody (Cell Signaling Technology Inc.,
Danvers, MA USA) was used at a dilution of 1:2000 and detected
with Amersham ECL Advance western blotting detection kit (GE
Healthcare UK Limited Amersham Place, Buckinghamshire, UK).
Results
Clinical analysis
The study group consisted of 17 probands from different
families: 15 male patients and 2 female carriers. Other novel
mutations were reported earlier as case studies [28,29] and
uploaded in Human Genetics database [30]. The well available
clinical details are summarized in Table 2. ccALD (Childhood
cerebral adrenoleukodystrophy) was the most common phenotype
in Indian population. The clinical features included neuroregres-
sion, seizures, deterioration of hearing, behaviour problem,
cognitive decline, speech problem and abnormal gait. Cerebral
MRI showed extensive demyelination in the parieto-occipital or
frontal white matter. Manifestation of AdolCALD (Adolescent
cerebral) and ACALD (adult cerebral adrenoleukodystrophy) are
similar to ccALD, but the progression is somewhat slower. Two
patients with AMN (adrenomyeloneuropathy) were included in
our study group. The nerve conduction studies in both the patients
Figure 1. Mutations and SNPs identified in the ABCD1 gene. The upper left panel depicts all the mutations and SNPs that are localized in the
schematic molecular structure of ALDP in the present study. The lower left panel shows the four novel mutations (a) c.1903_04insCCA/
Val635delinsAlaMet (TGG in antisense strand with reverse primer), (b) c.1979G.A/Arg660Gln, (c) c.1993_95delinsGAG/Lys665delinsGlu and (d)
c.1673T.C/Ile558Thr. The right panel shows the three novel SNPs (a) 476C/T (His30His), (b) 1950G/A (Ala650Ala) and (c) -32C/T in IVS9.
doi:10.1371/journal.pone.0025094.g001
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basal ganglia and mesencephalon demyelination but no cerebral
involvement. The patients had complaint of hypogonadism. The
progression of the inflammatory response in spinal cord was slow.
Two female carriers were identified on the basis of probands that
died partially diagnosed. The heterozygous females were asymp-
tomatic but had increased plasma VLCFA levels.
Mutational analysis
All mutations were present in the cytoplasmic domain of ALDP
as represented schematically in figure 1 in our study. No mutation
was present in the peroxisomal matrix. It is clear that each patient
possessed only one mutation in the ABCD1 gene (Table 3). In all,
there were 13 different mutations in 17 patients [Figure 1 and
Supporting Information S1 (a–i)]. Further, 10 non-recurrent and 3
recurrent mutations in 7 patients were present in Indian population.
Of these,8 weremissense (10patients),3 were frameshift(5 patients)
and 2 insertion/deletion (2 patients). One common recurrent
missense mutation c.796G.A (Gly266Arg) in exon 1 was present in
three patients from unrelated families with different phenotypes.
The remaining 2 recurrent mutations were frameshift, g.1866-
10G.A (Agr622fs) identified in IVS8 (intervening sequence 8) and
c.1939_40insGG (Ala646fs) in exon 9, each type was observed in
two different unrelated patients separately.
Of the 10 non-recurrent mutations in our study group i.e a
frameshift mutation c.110_117del8 (Val36fs) in exon 1 was
identified in an asymptomatic heterozygous female and 5 missense
mutations, c.904G.A (Glu302Lys) in exon 2, c.1202G.A
(Arg401Gln) in exon 3, c.1771C.T (Arg591Trp) in exon 7,
c.1816T.C (Ser606Pro) and c.1825G.A (Glu609Lys) in exon 8
were present in 5 different patients. The remaining 4 non-
recurrent mutations were novel which included 2 missense and 2
inframe amino acid deletion/insertion. The 2 missense novel
mutations c.1673T.C (Ile558Thr) and c.1979G.A (Arg660Gln)
were identified in exons 7 and 9 respectively. Inframe amino acid
deletion/insertion mutation c.1903_04insCCA (Val635delinsAla-
Met) and c.1993_95delinsGAG (Asn665delinsGln) were present in
exon 9 and 10 respectively.
The possible impact of missense mutations on the structure and
function of protein was predicted by Position-Specific Independent
Counts (PSIC) using Polymorphism Phenotyping (PolyPhen) tool.
High PSIC score difference (.0.5) indicates more damaging effect
of the substituted amino acid (http://genetics.bwh.harvard.edu/
pph/). Most of the missense mutations were predicted to have
deleterious effect on ALDP in our study (Table 3).
Protein expression analysis
The ALDP expression level was detected by western blot with
mouse anti-ALDP monoclonal antibody that bind to 495–648
fragment as a fusion protein. Its expression was found to be either
absent or decreased in all the patients (Figure 2). ALDP level in
one of the patients (number P05) could not be determined due to
insufficient availability of the sample. ALDP level was not
detectable in five patients (P02, P03, P10, P12 and P14). We
observed around fifty percent reduction in six patients (P01, P04,
P06, P13, P15 and P16) and much more in another two patients
(P11 and P17), (Figure 2). The remaining three (P07, P08 and P09)
showed intermediate level of ALDP. The variation in level of
proteins is random and not found to be associated with severity or
the phenotype of the disease. However, all patients with framshift
mutation showed relatively more decreased or total absence of
ALDP. Two patients containing the same mutation in the
intervening sequence (g.1866-10G.A/Arg622fs) showed different
pattern (totally absent in P03 while very mild expression in P11) of
ALDP. Interestingly, we found reverse trend of ALDP presence
(12/17=0.70) in our population as compared to other population.
Polymorphism analysis
In ABCD1 gene, a total of six SNPs were identified, out of them
three were novel (Table 4). Two novel SNPs, 90C/T (His30His) in
exon 1 and 1950G/A (Ala650Ala) in exon 9 were observed, one
each in unrelated healthy and patient samples. 1992-32C/T in
IVS9 was identified in two controls and one X-ALD patient
sample. The frequently occurring reported exonic SNP
(rs41314153) was located in exon 6 of the ABCD1 gene 1548G/
A (Leu516Leu) with MAF (minor allele frequency) ‘‘T’’ 16/84
Table 2. Neurological, radiological, biochemical and other clinical examination within different phenotypes of
adrenoleukodystrophy.
ccALD
1 AdolCALD
2 ACALD
3 AMN
4 A. Females
Relative frequencies (%) 47 17 12 12 12
Age of onset ,10 11.–21 .21 .19 At any age
Behavioural disturbances ++ Present in few - -
Impaired Cognition ++ + --
Dementia - Less frequent + --
Polyneuropathy - - - Axonal -
Impaired endocrine symptom Less frequent Appear in few Appear in most + -
Hypogonadism -- - + Not observed
Neuropsychological problem ++ + --
Progression Very rapid Rapid Rapid Slow No sign
Cerebral MRI Abnormality Parieto-occipital Fronal, parieto- occipital Occipital,corticospinal Basal ganglia mesencephalon Absent
Enhanced VLCFA in plasma ++ + + +
1ccALD-Childhood Adrenoleukodystrophy,
2AdolCALD- Adolescent cerebral Adrenoleukodystrophy,
3ACALD-Adult Cerebral Adrenoleukodystrophy,
4AMN-Adrenomyeloneuropathy. A.-Asymptomatic, (-) absent, (+) present.
doi:10.1371/journal.pone.0025094.t002
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adrenoleukodystrophy patients. Two other frequently occurring
SNPs viz. -59C/T (rs4148030) and 2238+8C/G (rs2229539), were
identified in 59 and 39 UTR respectively [(Table 4 and supporting
information S2 (a–c)]. The MAF ‘‘T’’ of 259C/T was observed
17.85% (15/84) and 20% (4/20) while MAF ‘‘G’’ of 2238+8C/G
was 28.57% (24/84) and 35% (7/20) in controls and patients
respectively.
Similar frequencies of different SNPs were observed in
unrelated X-ALD patients and controls. A case-control association
was not observed in general and further analysis did not reveal
evidence of association of polymorphisms with different X-ALD
phenotypes.
Discussion
The present study describes the clinical and genetic analysis of
17 X-linked adrenoleukodystrophy patients. Four novel mutations
were present in four unrelated patients. Three recurrent and ten
non-recurrent mutations in our study group were detected in the
ABCD1 gene. Presence of one mutation in each patient indicates
the significance of ABCD1 to be one of the most important
candidate genes responsible for the adrenoleukodystrophy syn-
drome. No complete gene deletions or nonsense mutations were
observed in Indian population. Of all 17 X-ALD patients, 10
possesed missense, 5 frameshift, and 2 inertion/deletion mutations
and all are present in the cytoplasmic domain of ALDP. We have
uploaded the mutations in the X-ALD database (http://www.x-
ald.nl/). The frequency of missense mutations in our population is
comparable to the X-ALD in other populations, most of which
result in the lower steady-state levels of ALDP (Figure 2).
However, no systematic study is present to support the predicted
structure and function of ALDP which is expressed by ABCD1
gene [31]. The effects of alteration of a single amino acid on the
biochemical role performed by this protein are difficult to infer,
but any missense mutation leading to decreased levels of ALDP
(while there is no effect on the levels of ABCD1 transcript) may
interfere with the peroxisomal targeting mechanisms of the newly
synthesized ALDP molecules and their correct membrane
insertion or their correct folding. Thus, most of the mutations
identified in our study might also interfere with any of these
processes. However, the possibility of degradation due to
misfolding of ALDP cannot be ruled out. We argue that the total
absence of ALDP in 5 patients supports this hypothesis. The
remaining patient showed reduced levels of ALDP as compared to
the control. Moreover, the PSCI score difference clearly predicted
their deleterious effect on ALDP (Table 3).
In June 2011, 1223 mutations in the ABCD1 gene, of which 574
(47%) are non-recurrent mutations, have been identified and listed
in X-ALD database (http://www.x-ald.nl/). They have been
described for all the 10 exons of the gene, and are generally
infrequent and usually confined to a single family. The majority of
X-ALD patients in our study group had non-recurrent (59%)
mutations. Single base pair substitution or point mutations
represented the majority (70%) of mutations. The remaining was
deletion/insertion of two or more nucleotides. All the point
mutations identified in the ABCD1 gene were transition mutations.
Most of the mutations (63%) were present in the functionally
relevant sites viz. transmembrane and ATP-binding domain of the
ALD protein which indicates that X-ALD mutations are not
Table 3. Molecular analysis of 17 patients with X-linked adrenoleukodystrophy syndrome.
Patients Phenotype
1 Age(Year) Sex Exon/IVS Mutation Type Mutations
Protein
Localization ALDP PSIC Score
5
P01* ccALD 4 M 9 Inframe del/ins c.1903_04delinsCCA/Val635delinsAlaMet NBF ++ -
P02* ccALD 5 M 9 Missense c.1979G.A/Arg660Gln - - 2.409
P03 ccALD 3 M IVS8
4 Frameshift g.1866-10G.A/Arg622fs Walker B
3 --
P04 ccALD 4.5 M 1 Missense c.796G.A/Gly266Arg TMD ++ + 2.539
P05 ccALD 6 M 9 Frameshift c.1939_40insGG/Ala646fs NBF n.d -
P06 ccALD 7 M 2 Missense c.904G.A/Glu302Lys TMD ++ 2.194
P07 ccALD 8 M 3 Missense c.1202G.A/Arg401Gln - ++ + 2.396
P08* ccALD 8 M 10 Inframe del/ins c.1993_95delinsGAG/Lys665delinsGlu - ++ -
P09 AdolCALD 11 M 1 Missense c.796G.A/Gly266Arg TMD ++ + 2.539
P10 AdolCALD 11 M 8 Missense c.1816T.C/Ser606Pro C sequence - 2.499
P11 AdolCALD 15 M IVS8 Frameshift g.1866-10G.A/Arg622fs Walker B + -
P12 ACALD 42 M 8 Missense c.1825G.A/Glu609Lys C sequence
3 - 2.075
P13* ACALD 46 M 7 Missense c.1673T.C/Ile558Thr NBF
3 ++ + 1.211
P14 AMN 26 M 9 Frameshift c.1939_40insGG/Ala646fs - - -
P15 AMN 35 M 1 Missense c.796G.A/Gly266Arg TMD
2 ++ + 2.539
P16 Asymptomatic 18 F 7 Missense c.1771C.T/Arg591Trp NBF ++ + 2.818
P17 Asymptomatic 26 F 1 Frameshift c.110_17del8/Val36fs - ++ -
*Novel Mutations,
1ccALD-Childhood Adrenoleukodystrophy, AMN-Adrenomyeloneuropathy, ACALD-Adult Cerebral Adrenoleukodystrophy, AdolCALD- Adolescent cerebral
Adrenoleukodystrophy.
2TMD: Transmembrane Domain.
3The nucleotide-binding fold (NBF), with Walker A and B regions – separated by the C sequence.
4IVS- Intervening Sequence,
5PolyPhen Position-Specific Independent Counts. Normal ALDP level (+++), Reduced ALDP level (++), Very low Level of ALDP (+), Absence of ALDP (2), n.d: not defined.
doi:10.1371/journal.pone.0025094.t003
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supports the contention that higher frequencies of disease causing
mutations are expected to be present in regions of the protein that
are crucial for its functions. Therefore, the gene analysis of the X-
ALD patients should initially include screening for mutations in
the functionally relevant region, and then the other region of the
gene by directsequencing. It is well known that geographical
distributions of ethnicity of patients have profound effects on
mutations. In some ethnic groups as in whites, exon 5 was the
possible hot-spot segment, while in Chinese population it was exon
Figure 2. ALDP expression level in peripheral blood mononuclear cells (PBMCs) in different patients. (a) Top Panel shows the western
blot of the patients ALDP level (except patient number P05) in total PBMCs lysate examined with mouse anti-ALDP monoclonal antibody as explained
in material and method. Lane 1 and 10 (Control by symbol ‘‘C’’), Lane 2 (P01, ccALD, V635delins A & M), Lane 3 (P02, ccALD, R660Q), Lane 4 (P03,
ccALD, R622fs), Lane 5 (P04, ccALD, G266R), Lane 6 (P06, ccALD, E302K), Lane 7 (P07, ccALD, R401Q), Lane 8 (P08, ccALD, K665delinsE), Lane 9 (P09,
AdolCALD, G266R), Lane 11 (P10, AdolCALD, S606P), Lane 12 (P11, AdolCALD, R622fs), Lane 13 (P12, ACALD, E609K), Lane 14 (P13, ACALD, I558T),
Lane 15 (P14, AMN, A646fs), Lane 16 (P15, AMN, G266R), Lane 17 (P16, asymptomatic female, R591W) and Lane 18 (P17, asymptomatic female,). The
lower panel shows the GAPDH as the loading control for each lane. (b) Densometric quantification of the ALDP in X-ALD patients normalized to
GAPDH. The number along the x-axis indicated the patient serial number and symbol ‘‘C’’ represents healthy control.
doi:10.1371/journal.pone.0025094.g002
Table 4. SNP analysis in ABCD1 gene in X-linked adrenoleukodystrophy cases and healthy controls.
Allele Gene Region SNP Controls (n=70) Patients (n=17) Status
59UTR (C/T) 59 UTR 259C/T T=15/84 (17.85%) T=4/20 (20%) Frequent
His30His* Exon 1 90C/T T =1/84 (Unique) T =1/20 (Unique) Unique
Leu516Leu Exon 6 1548G/A A=16/84 (19.04%) A=3/20 (15%) Frequent
Ala650Ala* Exon 9 1950G/A A=1/84 (Unique) A=1/20 (Unique) Unique
IVS9 (C/T)* IVS 9 1992-32C/T T=2/84 (2.38%) T=1/20 (Unique) Unique
39UTR (stop+8) 39 UTR 2238+8C/G G=24/84 (28.57%) G=7/20 (35%) Frequent
*Novel SNPs.
doi:10.1371/journal.pone.0025094.t004
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these regions [32–34]. Thus, a definite hot-spot mutation in Indian
patients could not be observed, although c.796G.A (Gly266Arg)
mutation in the transmembrane domain in exon 1 was present in
three unrelated patients of different phenotypes. Interestingly, a
novel intronic SNP 1992-32C/T was also observed in IVS9
in the patient with ccALD phenotype possessing c.796G.A
(Gly266Arg). The significance of such SNPs is not known.
However, the association of SNPs in linkage disequilibrium with
a functional mutation that modifies the expression of this gene
could not be excluded. We observed other two new exonic silent
SNPs which were, 90C/T (His30His) in exon 1 and1950G/A
(Ala650Ala) in exon 9 in two different unrelated ccALD patients
(P04 and P07, Table 3). However, both of these patients show
intermediate level of ALDP. The reports suggest that silent SNPs
can have the effect on rate of translation from mRNA to protein
[35]. The changes in the rate of translation, without any change in
the amino acid sequence which could affect the protein structure
and function, is intriguing and the mechanism in support of this
contention is further needed to be understood. The lack of large
number of common mutations with different ethnic groups and
the private nature of ABCD1 gene mutations in Indian population
may be attributed to the biodiversity in the population.
The clinical course of X-ALD is unpredictable. Moreover no
genotype (mutations)-phenotype (disease severity) correlation was
observed in our study on Indian population. Our study further
supports the fact that clinical manifestation of X-ALD is highly
variable, there is no correlation of between clinical phenotype,
VLCFA levels in plasma and geneotype, and the degree of loss of
function of ALDP is not related to disease severity [36,37]. This
lack of correlation suggest that some other genetic factors might
modulate the X-ALD phenotypes and several candidate genes
have been suggested as potential modifiers [38,39] or other yet
unidentified factors [15]. However, none of these genes have a
direct correlation with X-ALD phenotypes. Apart from this study,
only few recent studies are available on adrenoleukodystrophy
disease in India [28,29,40,41]. Therefore, a more detailed
investigation and analysis of this disease was obligatory to identify
new significant polymorphism and mutations and the variability of
allelic states in Indian Population. VLCFA level is at. borderline of
normal in 0.1% of affected males and 15% obligate heterozygotes
[42], but studies on mutation are the only reliable approach to
determine the genetic status of each individual and to rule out the
carrier status accurately. India has a multitude of genetically
diverse, unadmixed and isolated population groups and large
population size. These facts make India a fertile ground for gene-
hunting and validation of results from genome-wide association
and linkage studies. Our present study and further extended family
screening will definitely facilitate the understanding of this disease
more accurately which will help in early and more precise risk-
prediction, as well as aid in further prevention and therapy.
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